Capecitabine, Nivolumab, and Oxaliplatin
About
Membership operator: AND
Therapies: 3
Therapies
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy group.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Stomach Adenocarcinoma | Capecitabine, Nivolumab, Oxaliplatin | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Adenocarcinoma of the Gastroesophageal Junction | Capecitabine, Nivolumab, Oxaliplatin | |
| EMA (1) | HER2-negative, PD-L1 (CPS) >= 5 | Esophageal Adenocarcinoma | Capecitabine, Nivolumab, Oxaliplatin |